Ionizable lipids, compositions comprising same and uses thereof

By optimizing the structure of ionizable lipids and combining them with phospholipids, sterols and functional lipids to form efficient lipid nanoparticles, solving the problem of inefficient delivery of therapeutic nucleic acid drugs and achieving higher cells and animals Effects and safety of in vivo transfection.

CN119019272APending Publication Date: 2024-11-26CHINA PHARM UNIV
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411114840.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing therapeutic nucleic acid drugs are easily degraded by enzymes in the body and are difficult to enter cells, resulting in low delivery efficiency. The structure and composition of ionizable liposomes affect the efficiency of intracellular transfection and expression levels in animals, making it difficult to meet nucleic acid drugs. delivery requirements.

Method used

Develop a novel ionizable lipid for the preparation of lipid nanoparticles (LNPs) by combining branched chains containing ester bonds with long straight chains containing single or double bonds as tail chains for ionizable lipids. Optimize its structure to improve the delivery efficiency of nucleic acids. Specific methods include synthesizing ionizable lipids with a specific structure and combining them with phospholipids, sterols and functional lipids to form a drug delivery system.

Benefits of technology

It achieves higher nucleic acid delivery efficiency and safety, is better than existing ionizable lipids, significantly improves the transfection effect in cells and animals, reduces costs and reduces side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019272A_ABST
    Figure CN119019272A_ABST
Patent Text Reader

Abstract

The invention discloses an ionizable lipid which is selected from a compound with a structure as shown in a formula (I) or pharmaceutically acceptable salts thereof, X1 is # imgabs0, and # m is an integer from 2 to 10; g1 is hydroxyl or amino; x2 is # imgabs1; # n is an integer from 2 to 10; g2 is a branched chain alkyl group of C8-C18; and G3 is a C12-C16 alkenyl group with an unsaturated double bond. A cell transfection experiment and a mouse in-vivo transfection experiment show that the ionizable lipid shows excellent delivery efficiency which is superior to or close to the delivery efficiency of the existing ionizable lipid ALC-0315. The invention also discloses an application of the ionizable lipid in preparation of a drug delivery system. The invention also discloses a composition, the composition comprises a carrier, a therapeutic agent or a prophylactic agent, and the carrier comprises the ionizable lipid. # imgabs2 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicine and relates to a novel ionizable lipid, a composition containing the same and use thereof. Background Art

[0002] Many diseases faced by humans are related to abnormal protein expression, such as diabetes caused by insulin deficiency, and chronic myeloid leukemia is related to tyrosine kinase overexpression. Traditional small molecule drugs and monoclonal antibodies work by acting on proteins, but this requires that the target protein related to the disease itself has drug feasibility, and the research and development process of small molecule drugs and monoclonal antibodies is long and difficult.

[0003] The expression of intracellular proteins is regulated by messenger RNA (mRNA). Therapeutic nucleic acid drugs such as delivering mRNA or small interfering RNA (siRNA) into cells can affect the expression of cellular proteins, becoming an emerging treatment method. The advantages of therapeutic nucleic acid drugs include: first, the structure of the target protein itself can be ignored, mRNA can be directly designed, and delivered to the relevant parts to express the target protein to exert its effect; second, the corresponding siRNA sequence can be designed and delivered to the cell to inhibit the expression of the target protein mRNA, thereby treating the disease. Therapeutic nucleic acid drugs avoid the problem faced by traditional drugs that key disease proteins cannot be used as targets, as well as the long research and development process of targeted drugs.

[0004] Currently, the FDA has approved three nucleic acid drugs that use lipid nanoparticles (LNPs) as delivery systems, including Onpattro, a peripheral neuropathy drug from Alnylam Pharmaceuticals. [1] , Pfizer-BioNTech's new coronavirus vaccine BNT162b2 [2] Moderna's COVID-19 vaccine mRNA1273 [3] . Onpattro is the first siRNA drug approved by the FDA. It treats neuropathy caused by hereditary disease transthyretin-mediaamyloidosis (hATTR) by inhibiting the synthesis of transthyretin (TTR) protein in the liver. Both BNT162b2 and mRNA1273 use LNPs to deliver mRNA expressing the spike protein of the new coronavirus shell. After the mRNA is delivered to the cytoplasm, the spike protein is translated, thereby stimulating the body to produce an immune response. Nucleic acid drugs play an important role in disease prevention and have shown far-reaching application prospects in the fields of anti-tumor and immunotherapy.

[0005] The challenges faced by therapeutic nucleic acids as drugs are: they are charged biomacromolecules that are easily degraded by enzymes in the body; and they are difficult to enter cells, resulting in inability to function. Therefore, the key to the development of nucleic acid drugs is to build an effective delivery system to enable them to reach target cells and express or inhibit key proteins. LNPs are one of the most successful delivery systems at present. They encapsulate nucleic acids and deliver them to target organs through four components: ionizable lipids, auxiliary phospholipids (DSPC, DOPE, etc.), cholesterol, and polyethylene glycol. Among them, ionizable lipids play a vital role in the delivery process of LNPs. Ionizable lipids change their electrical properties with the pH value of the environment. During the preparation of LNPs, the solution is acidic, making the ionizable lipids positively charged, and negatively charged nucleic acid molecules can be encapsulated in them. During the delivery of LNPs in vivo, the encapsulated mRNA avoids degradation, and the environment is neutral, and the ionizable lipids are uncharged, which reduces the toxicity of LNPs and helps them enter cells. In the acidic endosomal environment of cells, LNPs become positively charged ions and can combine with negatively charged endosomal membranes, destroying the endosomal membranes to release nucleic acids into cells and affecting the expression of target proteins. In short, ionizable lipids can effectively deliver nucleic acids and are the main components that affect the delivery and expression efficiency of nucleic acid drugs. The development of new ionizable lipid compounds will provide more new materials for the delivery of nucleic acid drugs and meet the needs of preparing LNPs and compositions containing them.

[0006] At present, therapeutic nucleic acids require various ionizable lipids for delivering oligonucleotides, which are used to prepare therapeutic nucleic acids into LNPs, protect nucleic acids from being degraded and cleared in serum, are suitable for systemic or local delivery, and provide intracellular delivery of nucleic acids. Delivery efficiency is a key evaluation index of LNPs. LNPs with high delivery efficiency can effectively affect the expression of target proteins, improve safety and reduce costs. In addition, ionizable lipids also need to meet the requirements of low toxicity and no unacceptable side effects on the body. However, the relationship between the structure of ionizable liposomes and the intracellular transfection efficiency and in vivo expression level of LNPs composed of them has not yet been clarified. Minor structural differences in ionizable liposomes may lead to significant differences in the intracellular transfection efficiency and in vivo expression level of prepared LNPs.

[0007] References:

[0008] [1]Akinc A, Maier MA, Manoharan M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs [J]. Nature Nanotechnology, 2019, 14(12): 1084-1087.

[0009] [2]Polack FP,Thomas SJ,Kitchin N,et al.Safety and Efficacy of theBNT162b2 mRNA Covid-19 Vaccine[J].New England Journal of Medicine,2020,383(27):2603-2615.

[0010] [3]Baden LR,El Sahly HM,Essink B,et al.Efficacy and Safety of themRNA-1273SARS-CoV-2Vaccine[J].New England Journal of Medicine,2021,384(5):403-416. Summary of the invention

[0011] The purpose of the present invention is to optimize the structure of ionizable lipids, combine a branched chain containing an ester bond with a long straight chain containing a single bond or a double bond as the tail chain of the ionizable lipid, provide a new type of ionizable lipid, and use the ionizable lipids to prepare LNPs to introduce nucleic acids into cells. Compared with the LNPs prepared from existing ionizable lipids, the LNPs prepared from the ionizable lipids of the present invention have excellent delivery efficiency, show better delivery effects in both cell and animal experiments, and achieve protein expression of nucleic acids.

[0012] The objective of the present invention is achieved through the following technical solutions:

[0013] A novel ionizable lipid is selected from a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt thereof:

[0014]

[0015] in,

[0016] X1 is a C2-C10 methylene group ( m is an integer from 2 to 10);

[0017] G1 is hydroxyl or amine;

[0018] X2 is a C4-C10 methylene group ( n is an integer from 2 to 10);

[0019] G2 is a C8-C18 branched alkyl group;

[0020] G3 is a C12-C16 alkenyl group having an unsaturated double bond.

[0021] As a more preferred technical solution of the present invention, G1 is a hydroxyl group, G2 is A novel ionizable lipid is selected from a compound represented by formula (Ia) or a pharmaceutically acceptable salt thereof:

[0022]

[0023] X1 is m is an integer from 2 to 6;

[0024] X2 is n is an integer of 3 to 7, preferably an integer of 4 to 5;

[0025] G3 is selected from

[0026] As a further preferred technical solution of the present invention, a novel ionizable lipid is selected from a compound having a structure as shown in formula (Ia) or a pharmaceutically acceptable salt thereof, wherein X1 is m is an integer from 2 to 6, X2 is n is 4, G3 is selected from

[0027] X1 is m is 6, X2 is n is 5, G3 is selected from

[0028] X1 is m is 4, X2 is n is 4 or 5, G3 is selected from

[0029] As a further preferred technical solution of the present invention, a novel ionizable lipid is selected from a compound having a structure as shown in formula (Ia) or a pharmaceutically acceptable salt thereof, wherein X1 is m is 2, X2 is n is 4, G3 is selected from

[0030] X1 is m is 4, X2 is n is 4, G3 is selected from

[0031] X1 is m is 6, X2 is n is 4 or 5, G3 is selected from

[0032] X1 is m is 4, X2 is n is 4 or 5, G3 is selected from

[0033] Specifically, the ionizable lipid is selected from the compound with the structure shown below or a pharmaceutically acceptable salt thereof:

[0034]

[0035]

[0036] Another object of the present invention is to provide a method for preparing the ionizable lipid, the synthetic route of which is:

[0037]

[0038] Among them, X1, G1, X2, G2, G3 are as described above;

[0039] include:

[0040] Step (1), in the presence of an acid binding agent and a catalyst, as shown in the formula The unsaturated alcohol shown in the figure is reacted with p-toluenesulfonyl chloride to obtain compound II; wherein the molar ratio of the unsaturated alcohol to p-toluenesulfonyl chloride is 1.5:1 to 3:1; the reaction solvent is selected from one of dichloromethane, chloroform, acetonitrile, DMF and DMSO, and the reaction temperature is 25°C to 140°C; the acid binding agent is selected from one of triethylamine, potassium carbonate, sodium carbonate and N,N-diisopropylethylamine, and the molar ratio of the unsaturated alcohol to the acid binding agent is 1:1 to 1.5:1; the catalyst is selected from 4-dimethylaminopyridine, and the molar ratio of the unsaturated alcohol to the catalyst is 1:1 to 1.5:1;

[0041] Step (2), in the presence of an acidic catalyst, a halogenated alcohol such as BrCH2X2OH and a halogenated alcohol such as The carboxylic acid containing branched alkane is subjected to an esterification reaction to obtain compound III; wherein the molar ratio of the carboxylic acid to the halogenated alcohol is 1.15:1 to 2:1; the acid catalyst is p-toluenesulfonic acid, and the molar ratio of the acid catalyst to the halogenated alcohol is 1:1.5 to 1:2; the reaction solvent is selected from one of cyclohexane, toluene, dichloromethane, chloroform, acetonitrile, DMF and DMSO; the reaction temperature is 25°C to 140°C;

[0042] Step (3), in the presence of an acid binding agent and a catalyst, as shown in the formula The compound shown undergoes a substitution reaction with compound III to obtain an intermediate In the presence of an acid-binding agent, the intermediate Substitution reaction occurs with compound II to obtain the target compound shown in formula I;

[0043] in, The molar ratio with compound III is 0.5:1 to 15:1, preferably 4.5:1 to 5:1; The molar ratio with compound II is 1:1 to 1:1.25;

[0044] synthesis When the reaction solvent is selected from one of ethanol, acetonitrile, acetonitrile, DMF and DMSO, the reaction temperature is 25°C to 150°C, and the acid binding agent is selected from one of potassium carbonate, sodium carbonate, triethylamine, and N,N-diisopropylethylamine. The molar ratio of the catalyst to the acid binding agent is 5:1, and the catalyst is potassium iodide. The molar ratio to the catalyst is 50:1;

[0045] When synthesizing the target compound shown in formula I, the reaction solvent is selected from one of ethanol, acetonitrile, acetonitrile, DMF and DMSO, the reaction temperature is 25°C to 150°C, and the acid binding agent is selected from one of potassium carbonate, sodium carbonate, triethylamine, and N,N-diisopropylethylamine. The molar ratio of iodine to acid binding agent is 1:3.

[0046] Another object of the present invention is to provide use of the ionizable lipid in preparing a drug delivery system.

[0047] The drug delivery system comprises the ionizable lipid, and the molar ratio of the ionizable lipid to the carrier is 30:100 to 60:100.

[0048] Preferably, the drug delivery system comprises the ionizable lipid and at least one selected from phospholipids, sterols and functional lipids.

[0049] More preferably, the drug delivery system comprises ionizable lipids, phospholipids, sterols and functional lipids, and the molar ratio of the ionizable lipids, phospholipids, sterols and functional lipids is (30-60):(5-20):(25-45):(1-5), preferably 50:10:38.5:1.5.

[0050] Another object of the present invention is to provide a composition comprising a carrier, wherein the carrier comprises the ionizable lipid.

[0051] The molar ratio of the ionizable liposome to the carrier is 30:100 to 60:100.

[0052] In one embodiment, the molar ratio of the ionizable lipid to the carrier is 30:100, 40:100, 50:100, or 60:100.

[0053] Preferably, the carrier comprises the ionizable lipid and at least one selected from phospholipids, sterols and functional lipids.

[0054] In one embodiment, the carrier further comprises phospholipids. The molar ratio of the ionizable lipid to the phospholipid is 1:1 to 10:1, specifically selected from 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, and 10:1.

[0055] In one embodiment, the phospholipids include one or more of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin or their derivatives.

[0056] The phospholipids are selected from 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0Diether PC), 1-oleoyl-2-cholesteryl hemisuccinyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dialinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), dipalmitoyl phosphatidylglycerol (DPPG), palmitoyl oil One or more of the following: acylphosphatidylethanolamine (POPE), distearoyl-phosphatidyl-ethanolamine (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), 1-stearoyl-2-oleoyl-stearoylethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE).

[0057] In a preferred embodiment, the phospholipid is DOPE and / or DSPC.

[0058] In one embodiment, the carrier further comprises a sterol.

[0059] The molar ratio of the ionizable lipid to the sterol is 1:1 to 5:1, and can be specifically selected from 1:1, 1.3:1, 2:1, 3:1, 4:1, and 5:1.

[0060] In one embodiment, the sterol is selected from one or more of cholesterol, non-sterols, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, tomatine, ursolic acid, tocopherol, and corticosteroids.

[0061] In a preferred embodiment, the sterol is cholesterol.

[0062] In one embodiment, the carrier further comprises a functional lipid.

[0063] In one embodiment, the functional lipid is selected from one or more of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol.

[0064] For example, the functional lipids are selected from one or more of distearoylphosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG2000), dimyristoylglycerol-3-methoxy polyethylene glycol 2000 (DMG-PEG2000), and methoxy polyethylene glycol ditetradecanoyl acetamide (ALC-0159).

[0065] The molar ratio of the functional lipid to the carrier is 1:100 to 5:100.

[0066] In one embodiment, the molar ratio of the ionizable lipid to the carrier is 1:100, 1.5:100, 2:100, 2.5:100, 3:100, 3.5:100, 4:100, 4.5:100, or 5:100.

[0067] In one embodiment, the carrier includes ionizable lipids, phospholipids, sterols and functional lipids, and the molar ratio of the ionizable lipids, phospholipids, sterols and functional lipids is (30-60):(5-20):(25-45):(1-5), preferably 50:10:38.5:1.5.

[0068] In one embodiment, the composition further comprises a therapeutic or prophylactic agent.

[0069] In one embodiment, the therapeutic or prophylactic agent comprises a nucleic acid molecule.

[0070] For example, the therapeutic or prophylactic agent is a vaccine or a compound capable of eliciting an immune response.

[0071] In one embodiment, the therapeutic or prophylactic agent is a nucleic acid.

[0072] In the composition, the molar ratio of the ionizable lipid to the phosphate group in the nucleic acid molecule in the therapeutic agent or preventive agent is 1:1 to 20:1, preferably 3:1 to 15:1, and more preferably 6:1.

[0073] The "nucleic acid" may be a nucleotide polymer of any length, including but not limited to DNA, mRNA, small interfering RNA (siRNA), miRNA, circular RNA (circRNA), saRNA, micro RNA (miRNA), ribozyme, nucleic acid aptamer or a combination thereof; preferably mRNA.

[0074] In one embodiment, the composition is a nanoparticle preparation, the average particle size of the nanoparticle preparation is 90 to 210 nm, the polydispersity coefficient of the nanoparticle preparation is ≤0.3, and the zeta potential of the nanoparticle preparation is 0 to -3 mV.

[0075] Beneficial effects of the present invention:

[0076] The present invention utilizes ionizable lipids to encapsulate mRNA to prepare LNPs, with a particle size between 90 and 210 nm, a PDI of ≤0.3, a potential between 0 and -3 mV, an encapsulation rate of about 90%, and uniform data that meets the requirements.

[0077] Cell transfection experiments and mouse in vivo transfection experiments showed that the ionizable lipid of the present invention exhibited excellent delivery efficiency, which was better than the delivery efficiency of the existing ionizable lipid ALC-0315 or close to its delivery efficiency. BRIEF DESCRIPTION OF THE DRAWINGS

[0078] Figure 1 :Fluorescence imaging of HEK-293T cells transfected with LNP@eGFP mRNA.

[0079] Figure 2 :LNP@eGFP mRNA transfection fluorescence imaging; n=3, compared with the control group (PBS), ###P<0.001,

[0080] ##P<0.01, #P<0.05; compared with the positive control group (ALC-0315), ***P<0.001, **P<0.01, *P<0.05.

[0081] Figure 3: In vivo transfection imaging of LNP@LUC mRNA in mice; A: IVIS transfection imaging in mice; B: Quantitative analysis of fluorescence intensity in mice, n=3, compared with the positive control, **P<0.01, *P<0.05. DETAILED DESCRIPTION

[0082] In order to make the technical solutions and advantages of the present invention clearer, the technical solutions of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. All other embodiments obtained by ordinary technicians in this field based on the described embodiments without creative work belong to the scope of protection of the present invention.

[0083] The present invention may be implemented in other specific forms without departing from the basic attributes of the present invention. It should be understood that, without conflict, any and all embodiments of the present invention may be combined with the technical features in any other embodiment or multiple other embodiments to obtain other embodiments. The present invention includes other embodiments obtained by such combination.

[0084] Unless otherwise specified, all technical and scientific terms used in the present invention have the common meaning in the field to which the claimed subject matter belongs. If there are multiple definitions for a term, the definition herein shall prevail.

[0085] The term "pharmaceutically acceptable" as used herein refers to compounds or compositions that are chemically and / or toxicologically compatible with other ingredients constituting the formulation and / or with mammals with which they are used to prevent or treat a disease or condition.

[0086] The term "pharmaceutically acceptable salts" refers to the relatively non-toxic, inorganic or organic acid addition salts of compounds of the present invention.

[0087] The term "ionizable lipid" refers to a lipid that has a positive charge at a selected pH value.

[0088] In this experiment, ionizable lipid ALC-0315 was selected as the positive control drug.

[0089] The structure of ALC-0315 is as follows:

[0090]

[0091] Example 1

[0092] Synthesis of 5-((2-hydroxyethyl)(octadec-9-en-1-yl)amino)pentyl 2-hexyldecanoate (Compound O2-N5-Ole)

[0093] The synthesis path is as follows:

[0094]

[0095] Step 1: Synthesis of octadec-9-ene-1-methylbenzenesulfonate (compound Ts-18S)

[0096] Dissolve oleyl alcohol (200 mg, 0.75 mmol) and triethylamine (75.89 mg, 0.75 mmol) in dichloromethane and stir in an ice bath. Slowly add a mixed solution of p-toluenesulfonyl chloride (95.3 mg, 0.5 mmol) and 4-dimethylaminopyridine (91.63 mg, 0.75 mmol) in dichloromethane. After the addition is complete, remove the ice bath and react at room temperature for 4 hours. After the reaction is completed, wash the reaction solution with water, collect the organic phase, dry it over anhydrous Na2SO4, filter it, and concentrate the filtrate under vacuum. Purify the crude product by silica gel chromatography (eluent: PE:EA=40:1V / V) to obtain octadec-9-ene-1-methylbenzenesulfonate (83.7 mg, yield 39.67%).

[0097] C 25 H 42 O3S, MS (ES): m / z: 422.3.

[0098] 1 H NMR (300MHz, CDCl3) δppm: 7.8 (d, 2H); 7.45 (d, 2H); 5.3 (m, 2H); 4.0 (t, 2H); 2.4 (s, 3H); 2.2 (m, 4H); 1.2-1.5 (m, 24H); 0.88 (t, 3H).

[0099] Step 2: Synthesis of 5-bromopentyl 2-hexyldecanoate (Compound 5B)

[0100] 5-Bromohexanol (50 mg, 0.28 mmol) and 2-hexyldecanoic acid (84.97 mg, 0.33 mmol) were dissolved in cyclohexane, and p-toluenesulfonic acid (26.32 mg, 0.15 mmol) was added. The reaction system was heated to 110° C. and stirred at 110° C. for 12 h. After no more water was produced, the reaction was terminated. The reaction solution was washed 4 times with saturated brine, dried over Na2SO4, filtered, and the filtrate was concentrated under vacuum. The crude product was purified by silica gel chromatography (eluent: PE:EA=10:1V / V) to obtain 5-bromopentyl 2-hexyldecanoate (75.82 mg, yield 72.2%).

[0101] C 21 H 41 BrO2, MS (ES): m / z: 404.23.

[0102] 1H NMR (300MHz, CDCl3) δppm: 4.1 (t, 2H); 3.5 (t, 2H); 2.1 (m, 1H); 1.8 (m, 2H); 1.6 (m, 6H); 1.2-1.3 (m, 22H); 0.88 (t, 6H).

[0103] Step 3: Synthesis of 5-((2-hydroxyethyl)amino)pentyl 2-hexyldecanoate (Compound N2-5B)

[0104] 2-Aminoethanol (222.85 mg, 2.5 mmol) was dissolved in ethanol, potassium carbonate (69 mg, 0.5 mmol) and potassium iodide (8.3 mg, 0.05 mmol) were added, the reaction system was heated to 80°C, and an ethanol solution of 2-hexyldecanoic acid 5-bromopentyl ester (200 mg, 0.5 mmol) was slowly added dropwise to the reaction system while stirring, and stirring was continued at 80°C for 7 hours to terminate the reaction. The reaction solution was washed 4 times with saturated brine, dried over Na2SO4, filtered, and the filtrate was concentrated under vacuum, and the residue was purified by silica gel chromatography (eluent: DCM: MeOH: NH3·H2O = 10: 1: 0.2 V / V) to obtain 5-((2-hydroxyethyl)amino)pentyl 2-hexyldecanoate (87.8 mg, yield 45.6%).

[0105] C 23 H 47 NO3, MS (ES): m / z: 385.36.

[0106] 1 H NMR (300MHz, CDCl3) δppm: 4.8 (s, 1H); 4.1 (t, 2H); 3.7 (s, 1H); 3.5 (t, 2H); 2. 7(t,2H); 2.5(t,2H); 2.1(m,1H); 1.6(m,6H); 1.2-1.4(m,24H); 0.88(t,3H).

[0107] Step 4: Synthesis of 5-((2-hydroxyethyl)(octadec-9-en-1-yl)amino)pentyl 2-hexyldecanoate (compound O2-N5-Ole)

[0108] 5-((2-hydroxyethyl)amino)pentyl 2-hexyldecanoate (50 mg, 0.13 mmol) and octadec-9-ene-1-methylbenzenesulfonate (65.75 mg, 0.16 mmol) were dissolved in acetonitrile, potassium carbonate (53.90 mg, 0.39 mmol) was added, the reaction system was heated to 75 ° C, stirred for 10 h, and the reaction was terminated. The reaction solution was washed 4 times with saturated brine, dried over Na2SO4, filtered, and the filtrate was concentrated under vacuum, and the residue was purified by silica gel chromatography (eluent: DCM: MeOH = 10: 1 V / V) to obtain 5-((2-hydroxyethyl) (octadec-9-ene-1-yl)amino)pentyl 2-hexyldecanoate (43.32 mg, yield 52.43%).

[0109] C 41 H 81 NO3, MS (ES): m / z: 635.62.

[0110] 1 H NMR (300MHz, CDCl3) δppm: 5.3 (t, 2H); 4.2 (s, 1H); 4.0 (t, 2H); 3.4 (t, 2H); 3.0 ( t,4H);2.6(t,2H);2.1-2.2(m,5H);1.6(m,6H);1.2-1.4(m,48H);0.88(t,6H).

[0111] Example 2

[0112] Synthesis of 6-((2-hydroxyethyl)(octadec-9-en-1-yl)amino)2-hexyldecanoate (compound O2-N6-Ole)

[0113] The synthesis path is as follows:

[0114]

[0115] Step 1: Synthesis of 6-bromopentyl 2-hexyldecanoate (Compound 6B)

[0116] Using 6-bromohexanol (423.7 mg, 2.34 mmol) and 2-hexyldecanoic acid (500 mg, 1.95 mmol) as raw materials, the method for preparing compound 5B according to Example 1 was used to obtain 6-bromopentyl 2-hexyldecanoate (410.6 mg, 50.2%).

[0117] 1 H NMR (300MHz, CDCl3) δppm: 4.1 (t, 2H); 3.5 (t, 2H); 2.1 (m, 1H); 1.8 (m, 2H); 1.6 (m, 6H); 1.2-1.3 (m, 24H); 0.88 (t, 6H).

[0118] Step 2: Synthesis of 6-((2-hydroxyethyl)amino)hexyl 2-hexyldecanoate (Compound N2-6B)

[0119] Using compound 6B (200 mg, 0.478 mmol) and ethanolamine (145.37 mg, 2.38 mmol) as raw materials, the method for preparing compound N2-5B according to Example 1 was used to obtain 2-hexyldecanoic acid 6-((2-hydroxyethyl)amino)hexyl ester (72.0 mg, yield 37.87%).

[0120] 1 H NMR (300MHz, CDCl3) δppm: 4.8 (s, 1H); 4.1 (t, 2H); 3.7 (s, 1H); 3.5 (t, 2H); 2. 7(t,2H); 2.5(t,2H); 2.1(m,1H); 1.6(m,6H); 1.2-1.4(m,26H); 0.88(t,3H).

[0121] Step 3: Synthesis of 6-((2-hydroxyethyl)(octadec-9-en-1-yl)amino)2-hexyldecanoate (compound O2-N6-Ole)

[0122] Using compound N2-6B (36 mg, 0.090 mmol) and compound Ts-18S (45.61 mg, 0.108 mmol) as raw materials, the method for preparing compound O2-N5-Ole according to Example 1 was used to obtain the target compound 6-((2-hydroxyethyl)(octadec-9-en-1-yl)amino)2-hexyldecanoate (21.94 mg, yield 37.5%).

[0123] C 42 H 83 NO3, MS (ES): m / z (M+H) 649.64.

[0124] 1 H NMR (300MHz, CDCl3) δppm: 5.3 (t, 2H); 4.2 (s, 1H); 4.0 (t, 2H); 3.4 (t, 2H); 3.0 ( t,4H);2.6(t,2H);2.1-2.2(m,5H);1.6(m,6H);1.2-1.4(m,50H);0.88(t,6H).

[0125] Example 3

[0126] Synthesis of 5-((4-hydroxybutyl)(octadec-9-en-1-yl)amino)pentyl-2-hexyldecanoate (Compound O4-N5-Ole)

[0127] The synthesis path is as follows:

[0128]

[0129] Step 1: Synthesis of 5-((4-hydroxybutyl)amino)pentyl 2-hexyldecanoate (Compound N4-5B)

[0130] Using compound 5B (200 mg, 0.49 mmol) and 4-aminobutanol (218.25 mg, 2.45 mmol) as raw materials, the method for preparing compound N2-5B according to Example 1 was used to obtain 5-((4-hydroxybutyl)amino)pentyl 2-hexyldecanoate (183.75 mg, yield 44.45%).

[0131] 1 H NMR (300MHz, CDCl3) δppm: 4.8 (s, 1H); 4.1 (t, 2H); 3.7 (s, 1H); 3.5 (t, 2H); 2. 7(t,2H); 2.5(t,2H); 2.1(m,1H); 1.6(m,8H); 1.2-1.4(m,26H); 0.88(t,3H).

[0132] Step 2: Synthesis of 5-((4-hydroxybutyl)(octadec-9-en-1-yl)amino)pentyl-2-hexyldecanoate (Compound O4-N5-Ole)

[0133] Using compound N4-5B (100 mg, 0.241 mmol) and compound Ts-18S (122.13 mg, 0.289 mmol) as raw materials, the method for preparing compound O2-N5-Ole according to Example 1 was used to obtain the target compound 5-((4-hydroxybutyl)(octadec-9-en-1-yl)amino)pentyl-2-hexyldecanoate (53.0 mg, yield 33.11%).

[0134] C 43 H 85 NO3, MS (ES): m / z: 663.65.

[0135] 1 H NMR (300MHz, CDCl3) δppm: 5.3 (t, 2H); 4.2 (s, 1H); 4.0 (t, 2H); 3.4 (t, 2H); 3.0 ( t,4H);2.6(t,2H);2.1-2.2(m,5H);1.6(m,8H);1.2-1.4(m,50H);0.88(t,6H).

[0136] Example 4

[0137] Synthesis of 6-((4-hydroxybutyl)(octadec-9-en-1-yl)amino)2-hexyldecanoate (Compound O4-N6-Ole)

[0138] The synthesis path is as follows:

[0139]

[0140] Step 1: Synthesis of 6-((4-hydroxybutyl)amino)hexyl 2-hexyldecanoate (Compound N4-6B)

[0141] Using compound 6B (200 mg, 0.48 mmol) and 4-aminobutanol (213.8 mg, 2.40 mmol) as raw materials, the method for preparing compound N2-5B according to Example 1 was used to obtain 2-hexyldecanoic acid 6-((4-hydroxybutyl)amino)hexyl ester (117.4 mg, yield 57.2%).

[0142] 1 H NMR (300MHz, CDCl3) δppm: 4.8 (s, 1H); 4.1 (t, 2H); 3.7 (s, 1H); 3.5 (t, 2H); 2. 7(t,2H); 2.5(t,2H); 2.1(m,1H); 1.6(m,8H); 1.2-1.4(m,28H); 0.88(t,3H).

[0143] Step 2: Synthesis of 6-((4-hydroxybutyl)(octadec-9-en-1-yl)amino)2-hexyldecanoate (compound O4-N6-Ole)

[0144] Using compound N4-6B (50 mg, 0.117 mmol) and compound Ts-18S (59.08 mg, 0.140 mmol) as raw materials, the method for preparing compound O2-N5-Ole according to Example 1 was used to obtain the target compound 6-((4-hydroxybutyl)(octadec-9-en-1-yl)amino)2-hexyldecanoate (41.6 mg, yield 52.43%).

[0145] C 44 H 87 NO3, MS (ES): m / z: 677.6686.

[0146] 1 H NMR (300MHz, CDCl3) δppm: 5.3 (t, 2H); 4.2 (s, 1H); 4.0 (t, 2H); 3.4 (t, 2H); 3.0 ( t,4H);2.6(t,2H);2.1-2.2(m,5H);1.6(m,8H);1.2-1.4(m,52H);0.88(t,6H).

[0147] Example 5

[0148] Synthesis of 5-((6-hydroxyhexyl)(octadec-9-en-1-yl)amino)pentyl-2-hexyldecanoate (Compound O6-N5-Ole)

[0149] The synthesis path is as follows:

[0150]

[0151] Step 1: Synthesis of 5-((6-hydroxyhexyl)amino)pentyl 2-hexyldecanoate (Compound N6-5B)

[0152] Using compound 5B (200 mg, 0.49 mmol) and 6-aminohexanol (287.14 mg, 2.45 mmol) as raw materials, the method for preparing compound N2-5B according to Example 1 was used to obtain 5-((6-hydroxyhexyl)amino)pentyl 2-hexyldecanoate (65.4 mg, yield 30.21%).

[0153] 1 H NMR (300MHz, CDCl3) δppm: 4.8 (s, 1H); 4.1 (t, 2H); 3.7 (s, 1H); 3.5 (t, 2H); 2. 7(t,2H); 2.5(t,2H); 2.1(m,1H); 1.6(m,8H); 1.2-1.4(m,30H); 0.88(t,3H).

[0154] Step 2: Synthesis of 5-((6-hydroxyhexyl)(octadec-9-en-1-yl)amino)pentyl-2-hexyldecanoate (compound O6-N5-Ole)

[0155] Using compound N6-5B (100 mg, 0.226 mmol) and compound Ts-18S (114.5 mg, 0.271 mmol) as raw materials, the method for preparing compound O2-N5-Ole according to Example 1 was used to obtain the target compound 5-((6-hydroxyhexyl)(octadec-9-en-1-yl)amino)pentyl-2-hexyldecanoate (65.4 mg, yield 42%).

[0156] C 45 H 89 NO3, MS (ES): m / z: 691.68.

[0157] 1H NMR (300MHz, CDCl3) δppm: 5.3 (t, 2H); 4.2 (s, 1H); 4.0 (t, 2H); 3.4 (t, 2H); 3.0 ( t,4H);2.6(t,2H);2.1-2.2(m,5H);1.6(m,8H);1.2-1.4(m,54H);0.88(t,6H).

[0158] Example 6

[0159] Synthesis of 6-((6-hydroxybutyl)(octadec-9-en-1-yl)amino)2-hexyldecanoate (compound O6-N6-Ole)

[0160] The synthesis path is as follows:

[0161]

[0162] Step 1: Synthesis of 6-((6-hydroxyhexyl)amino)hexyl 2-hexyldecanoate (N6-6B)

[0163] Using compound 6B (200 mg, 0.47 mmol) and 6-aminohexanol (275.42 mg, 2.35 mmol) as raw materials, the method for preparing compound N2-5B according to Example 1 was used to obtain 2-hexyldecanoic acid 6-((6-hydroxyhexyl)amino)hexyl ester (64.0 mg, yield 29.91%).

[0164] 1 H NMR (300MHz, CDCl3) δppm: 4.8 (s, 1H); 4.1 (t, 2H); 3.7 (s, 1H); 3.5 (t, 2H); 2. 7(t,2H); 2.5(t,2H); 2.1(m,1H); 1.6(m,8H); 1.2-1.4(m,32H); 0.88(t,3H).

[0165] Step 2: Synthesis of 6-((6-hydroxybutyl)(octadec-9-en-1-yl)amino)2-hexyldecanoate (compound O6-N6-Ole)

[0166] Using compound N6-6B (65 mg, 0.187 mmol) and TS-18S (95 mg, 0.224 mmol) as raw materials, the method for preparing compound O2-N5-Ole according to Example 1 was used to obtain the target compound 6-((6-hydroxybutyl)(octadec-9-en-1-yl)amino)2-hexyldecanoate (52.5 mg, yield 40.0%).

[0167] C 46 H 91NO3, MS (ES): m / z: 705.70.

[0168] 1 H NMR (300MHz, CDCl3) δppm: 5.3 (t, 2H); 4.2 (s, 1H); 4.0 (t, 2H); 3.4 (t, 2H); 3.0 ( t,4H);2.6(t,2H);2.1-2.2(m,5H);1.6(m,8H);1.2-1.4(m,56H);0.88(t,6H).

[0169] Example 7

[0170] Synthesis of 5-((2-hydroxyethyl)((9Z,12Z)-octadec-9,12-dien-1-yl)amino)pentyl-2-hexyldecanoate (compound O2-N5-DLin)

[0171] The synthesis path is as follows:

[0172]

[0173] Step 1: Synthesis of (9Z,12Z)-octadec-9,12-dien-1-yl 4-methylbenzenesulfonate (compound Ts-18D)

[0174] Using 4-methylbenzenesulfonyl chloride (200 mg, 1.05 mmol) and linoleyl alcohol (335.74 mg, 1.26 mmol) as raw materials, the method for preparing compound Ts-18S according to Example 1 was used to obtain (9Z,12Z)-octadec-9,12-dien-1-yl 4-methylbenzenesulfonate (278.4 mg, yield 63.03%).

[0175] 1 H NMR (300MHz, CDCl3) δppm: 7.8 (d, 2H); 7.45 (d, 2H); 5.4 (m, 2H); 5.3 (m, 2H); 4 .0(t,2H);2.8(t,2H);2.4(s,3H);2.2(q,4H);1.2-1.5(m,18H);0.88(t,3H).

[0176] Step 2: Synthesis of 5-((2-hydroxyethyl)((9Z,12Z)-octadec-9,12-dien-1-yl)amino)pentyl-2-hexyldecanoate (compound O2-N5-DLin)

[0177] Compound N2-5B (100 mg, 0.259 mmol) and Ts-18D (130.73 mg, 0.311 mmol) were dissolved in acetonitrile, potassium carbonate (107.33 mg, 0.777 mmol) was added, and the mixture was heated to 85°C for overnight reaction to terminate the reaction. After the reaction was completed, saturated brine was added for washing 4 times, and the mixture was dried over Na2SO4, filtered, and the filtrate was concentrated under vacuum, and the residue was purified by silica gel chromatography to obtain 5-((2-hydroxyethyl)((9Z,12Z)-octadec-9,12-dien-1-yl)amino)pentyl-2-hexyldecanoate (54.36 mg, yield 33.1%).

[0178] C 41 H 79 NO3, MS (ES): m / z: 633.61.

[0179] 1 H NMR (300MHz, CDCl3) δppm: 5.4 (m, 2H); 5.3 (m, 2H); 4.2 (s, 1H); 4.1 (t, 2H); 3.4 (t, 2H); 3.0 ( t,4H); 2.8(t,2H); 2.6(t,2H); 2.1-2.2(m,5H); 1.6(m,6H); 1.2-1.4(m,42H); 0.88(t,6H).

[0180] Example 8

[0181] Synthesis of 6-((2-hydroxyethyl)((9Z,12Z)-octadec-9,12-dien-1-yl)amino)2-hexyldecanoate (compound O2-N6-DLin)

[0182] The synthesis path is as follows:

[0183]

[0184] Using compound N2-6B (99.4 mg, 0.248 mmol) and compound Ts-18D (124.93 mg, 0.297 mmol) as raw materials, according to the synthesis method of compound O2-N5-DLin in Example 7, the target compound 6-((2-hydroxyethyl)((9Z,12Z)-octadec-9,12-dien-1-yl)amino)2-hexyldecanoate (67.0 mg, yield 41.68%) was obtained.

[0185] C 42 H 81 NO3, MS (ES): m / z: 647.62.

[0186] 1H NMR (300MHz, CDCl3) δppm: 5.4 (m, 2H); 5.3 (m, 2H); 4.2 (s, 1H); 4.1 (t, 2H); 3.4 (t, 2H); 3.0 ( t,4H); 2.8(t,2H); 2.6(t,2H); 2.1-2.2(m,5H); 1.6(m,6H); 1.2-1.4(m,42H); 0.88(t,6H).

[0187] Example 9

[0188] Synthesis of 5-((4-hydroxybutyl)((9Z,12Z)-octadec-9,12-dien-1-yl)amino)pentyl-2-hexyldecanoate (compound O4-N5-DLin)

[0189] The synthesis path is as follows:

[0190]

[0191] Using compound N4-5B (102.4 mg, 0.248 mmol) and compound Ts-18D (125 mg, 0.297 mmol) as raw materials, according to the synthesis method of compound O2-N5-DLin in Example 7, the target compound 5-((4-hydroxybutyl)((9Z, 12Z)-octadec-9,12-dien-1-yl)amino)pentyl-2-hexyldecanoate (85.0 mg, yield 53.11%) was obtained.

[0192] C 43 H 83 NO3, MS (ES): m / z: 661.64.

[0193] 1 H NMR (300MHz, CDCl3) δppm: 5.4 (m, 2H); 5.3 (m, 2H); 4.2 (s, 1H); 4.1 (t, 2H); 3.4 (t, 2H) ;3.0(t,6H);2.8(t,2H);2.1-2.2(m,5H);1.6(m,8H);1.2-1.4(m,44H);0.88(t,6H).

[0194] Example 10

[0195] Synthesis of 6-((4-hydroxybutyl)((9Z,12Z)-octadec-9,12-dien-1-yl)amino)2-hexyldecanoate (compound O4-N6-DLin)

[0196] The synthesis path is as follows:

[0197]

[0198] Using compound N4-6B (110 mg, 0.257 mmol) and compound Ts-18D (130 mg, 0.31 mmol) as raw materials, according to the synthesis method of compound O2-N5-DLin in Example 7, the target compound 6-((4-hydroxybutyl)((9Z, 12Z)-octadec-9,12-dien-1-yl)amino)2-hexyldecanoate (62.7 mg, yield 36.1%) was obtained.

[0199] C 44 H 85 NO3, MS (ES): m / z: 675.65.

[0200] 1 H NMR (300MHz, CDCl3) δppm: 5.4 (m, 2H); 5.3 (m, 2H); 4.2 (s, 1H); 4.1 (t, 2H); 3.4 (t, 2H) ;3.0(t,6H);2.8(t,2H);2.1-2.2(m,5H);1.6(m,8H);1.2-1.4(m,46H);0.88(t,6H).

[0201] Embodiment 11

[0202] Synthesis of 5-((6-hydroxyhexyl)((9Z,12Z)-octadec-9,12-dien-1-yl)amino)pentyl-2-hexyldecanoate (compound O6-N5-DLin)

[0203] The synthesis path is as follows:

[0204]

[0205] Using compound N6-5B (100 mg, 0.23 mmol) and compound Ts-18D (116 mg, 0.276 mmol) as raw materials, according to the synthesis method of compound O2-N5-DLin in Example 7, the target compound 5-((6-hydroxyhexyl)((9Z,12Z)-octadec-9,12-dien-1-yl)amino)pentyl-2-hexyldecanoate (64.3 mg, yield 42.3%) was obtained.

[0206] C 45 H 87 NO3, MS (ES): m / z: 689.67

[0207] 1H NMR (300MHz, CDCl3) δppm: 5.4 (m, 2H); 5.3 (m, 2H); 4.7 (s, 1H); 4.1 (t, 2H); 3.6 (t, 2H) ;3.0(t,6H);2.8(t,2H);;2.1-2.2(m,5H);1.6(m,8H);1.2-1.4(m,48H);0.88(t,6H).

[0208] Example 12

[0209] Synthesis of 6-((6-hydroxyhexyl)((9Z,12Z)-octadec-9,12-dien-1-yl)amino)pentyl-2-hexyldecanoate (compound O6-N6-DLin)

[0210] The synthesis path is as follows:

[0211]

[0212] Using compound N6-6B (130 mg, 0.285 mmol) and compound Ts-18D (144.0 mg, 0.342 mmol) as raw materials, according to the synthesis method of compound O2-N5-DLin in Example 7, the target compound 6-((6-hydroxyhexyl)((9Z,12Z)-octadec-9,12-dien-1-yl)amino)pentyl-2-hexyldecanoate (64 mg, yield 31.8%) was obtained.

[0213] C 46 H 89 NO3, MS (ES): m / z: 703.68.

[0214] 1 H NMR (300MHz, CDCl3) δppm: 5.4 (m, 2H); 5.3 (m, 2H); 4.7 (s, 1H); 4.1 (t, 2H); 3.6 (t, 2H) ;3.0(t,6H);2.8(t,2H);2.1-2.2(m,5H);1.6(m,8H);1.2-1.4(m,50H);0.88(t,6H).

[0215] Embodiment 13

[0216] Preparation of nanolipid particles (LNP@eGFP mRNA)

[0217] The ionizable lipids prepared in Examples 1 to 12 were dissolved in ethanol with DSPC (Yuan Ye Biotechnology Co., Ltd.), cholesterol (Yuan Ye Biotechnology Co., Ltd.), and DMG-PEG2000 (Yuan Ye Biotechnology Co., Ltd.) at a molar ratio of 50:10:38.5:1.5 to obtain an organic phase; eGFP mRNA was dissolved in 100 mM citrate buffer (pH = 4.0) to obtain an aqueous phase; the amine (N) of the ionizable lipids and eGFP The molar ratio of phosphate (N / P) of mRNA is 6:1. A microfluidic device (Shanghai Pengzan Biotechnology Co., Ltd.) is used to mix the organic phase and the aqueous phase (the volume ratio of the aqueous phase to the organic phase is 3:1) at a flow rate of 4 mL / min to prepare nanolipid particles; ALC-0315 (Aikangtaisheng Therapeutics Co., Ltd.) and Exfect (Novazan Co., Ltd.) are used instead of the ionizable lipid of the present invention as positive controls; after diluting 5 times the volume with PBS buffer solution, a 30KD ultrafiltration tube is used to centrifuge at a speed of 5000 r / min at a temperature of 4°C to remove ethanol, and then the volume is fixed to 500 μL with PBS buffer solution, and the particle size, polydispersity index (PDI), potential and encapsulation efficiency of the nanolipid particles are measured.

[0218] Determination of particle size, polydispersity index (PDI), potential and encapsulation efficiency of nanolipid particles

[0219] The particle size, polydispersity index (PDI) and potential were determined using a Malvern laser particle size analyzer, and the encapsulation efficiency of the nanolipid particles was determined using Ribogreen.

[0220] Take 100 μL of sample, dilute to 1 mL with PBS, add to the cuvette sample pool, and repeat the measurement 3 times for each sample. The measurement conditions are: 90° scattering angle, 25°C.

[0221] Take 100 μL of sample, dilute it to 1 mL with PBS, add it to the potential cell, and measure each sample 3 times.

[0222] Take a small amount of sample and use Quant-iT TM RiboGreen TM The RNA detection kit was used to measure the fluorescence intensity and calculate the encapsulation efficiency.

[0223] Table 1. Particle size, polydispersity index (PDI), potential and encapsulation efficiency of nanolipid particles

[0224]

[0225] As shown in Table 1, the particle size of the nanolipid particles is between 100-150 nm, the PDI is between 0.1-0.25, the potential is between -0.5 mv and -2.5 mv, the encapsulation efficiency is about 90%, and the data are uniform and meet the requirements.

[0226] Embodiment 14

[0227] Transfection of HEK-293T cells with LNP@eGFP mRNA

[0228] Cell culture: HEK-293T cells were resuspended in DMEM + 10% FBS complete medium and cultured in a 37°C, 5% CO2 incubator. After multiple passages, the cells were resuspended at a cell concentration of 2.2×10 6 Pieces / mL.

[0229] Plating: Add 400 μL of DMEM+10% FBS complete medium and 100 μL of cell suspension to a 24-well plate, shake evenly, and culture in an incubator for 12 hours.

[0230] Administration: Before administration, the old culture medium was aspirated, and 500 μL of fresh complete culture medium was added. The lipid nanoparticles LNP@eGFP mRNA prepared in Example 13 were administered to each well, and the amount of eGFP mRNA administered to each well was controlled to be 1 μg. An equal amount of PBS was used instead of LNP@eGFP mRNA as a control group, and an equal amount of lipid nanoparticles prepared by ALC-0315 in Example 13 was used as a positive control group. Three replicates were performed in each group, and the cells were shaken evenly. The cells were cultured for 24 hours, and fluorescence observation was performed using an inverted fluorescence microscope.

[0231] Depend on Figure 1 It can be seen that all lipid nanoparticles can express green fluorescence in HEK-293T cells; quantitative analysis is shown in Figure 2 , indicating that O2-N5-Ole, O6-N5-Ole, O6-N6-Ole, O4-N5-Dlin and O4-N6-DLin showed significantly better transfection ability in cells than the positive control ALC-031, and O4-N5-Ole showed comparable transfection ability to the positive control ALC-031.

[0232] Embodiment 15

[0233] In vivo delivery of ionizable lipid carriers

[0234] In vitro verification by HEK-293T cells showed that 6 ionizable lipids had good transfection ability. This experiment was conducted according to Example 13 "Nanolipid Particle Preparation", except that eGFP mRNA was replaced with an equal amount of LUC mRNA, and the above 6 ionizable lipids and positive control ALC-0315 were used to encapsulate LUC mRNA (luciferase mRNA) to prepare LNP@LUCmRNA, and animal live imaging was performed to screen out the optimal ionizable lipid.

[0235] The dosage of nanolipid particles was 2 μg LUC mRNA per mouse, which was injected into the quadriceps muscle of the calf on both sides of the mouse. Six hours later, the luciferase potassium salt substrate was intraperitoneally injected at a dosage of 150 mg / kg. Ten minutes after the injection, the in vivo imaging instrument (IVIS) was used to detect and evaluate the fluorescence imaging effect.

[0236] The delivery effect of nanolipid particles is shown in Figure 3 . Compared with the positive control ALC-0315, O2-N5-Ole showed a better delivery effect, and O6-N5-Ole showed a similar delivery effect. Under the same structure, when X1 is a short chain, it may have a better substitution effect than a long chain, and the Ole tail chain has a better delivery effect than the DLin tail chain. And when the nanolipid particles prepared by the ionizable lipids of the present invention are injected intramuscularly, the drug mainly accumulates in the muscle at the injection site and will not circulate with the body to other organs such as the liver, which can reduce the toxic side effects caused by off-target.

Claims

1. An ionizable lipid selected from a compound represented by formula (I) or a pharmaceutically acceptable salt thereof: in, X1 is m is an integer from 2 to 10; G1 is hydroxyl or amine; X2 is n is an integer from 2 to 10; G2 is a C8-C18 branched alkyl group; G3 is a C12-C16 alkenyl group having an unsaturated double bond.

2. An ionizable lipid selected from a compound represented by formula (Ia) or a pharmaceutically acceptable salt thereof: in, X1 is m is an integer from 2 to 6; X2 is n is an integer of 3 to 7, preferably an integer of 4 to 5; G3 is selected from 3. The ionizable lipid according to claim 2, characterized in that: X1 is m is an integer from 2 to 6, X2 is n is 4, G3 is selected from X1 is m is 6, X2 is n is 5, G3 is selected from X1 is m is 4, X2 is n is 4 or 5, G3 is selected from 4. The ionizable lipid according to claim 3, characterized in that: X1 is m is 2, X2 is n is 4, G3 is selected from X1 is m is 4, X2 is n is 4, G3 is selected from X1 is m is 6, X2 is n is 4 or 5, G3 is selected from X1 is m is 4, X2 is n is 4 or 5, G3 is selected from 5. An ionizable lipid selected from a compound having the structure shown below or a pharmaceutically acceptable salt thereof:

6. Use of the ionizable lipid described in any one of claims 1 to 5 in the preparation of a drug delivery system.

7. A composition, characterized in that: The composition comprises a carrier, a therapeutic agent or a preventive agent, wherein the carrier comprises the ionizable lipid according to any one of claims 1 to 5, and the molar ratio of the ionizable lipid to the carrier is 30:100 to 60:100; and the therapeutic agent or the preventive agent comprises a nucleic acid molecule.

8. The composition according to claim 7, characterized in that: The carrier comprises the ionizable lipid and at least one selected from phospholipids, sterols and functional lipids.

9. The composition according to claim 7, characterized in that: The carrier comprises ionizable lipids, phospholipids, sterols and functional lipids, and the molar ratio of the ionizable lipids, phospholipids, sterols and functional lipids is (30-60):(5-20):(25-45):(1-5), preferably 50:10:38.5:1.

5.

10. The composition according to any one of claims 7 to 9, characterized in that: In the composition, the molar ratio of the ionizable lipid to the phosphate group in the nucleic acid molecule in the therapeutic agent or preventive agent is 1:1 to 20:1, preferably 3:1 to 15:1, and more preferably 6:1.

Citation Information

Patent Citations

  • Lipid compound and composition thereof

    CN113185421A

  • Carbon core cationic lipid

    CN118265692A

  • Compounds and compositions for delivery of therapeutic agents

    CN118369308A

  • Lipid compound and the composition thereof

    WO2022112855A1

  • Lipid and composition used for delivery

    WO2023125738A1